US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
NEW YORK, Feb. 01, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Esperion Therapeutics, Inc. (“Esperion”) (NASDAQ:ESPR) between August 18, 2015 and September 28, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of Michigan. To get more information go to: http://zlk.9nl.com/esperion-espr.
The complaint alleges that Defendants issued false and misleading statements regarding the Company’s business and prospects, including that there was no clear path to approval for ETC-1002, the Company’s lead product candidate designed to lower LDL-cholesterol levels, and that the FDA had encouraged the Company to initiate a cardiovascular outcomes trial (“CVOT”) and that completion of a CVOT could be necessary prior to approval of ETC-1002.
On August 17, 2015, Esperion reported to investors material events from an August 2015 meeting with the FDA; the Company stated that during the meeting it was informed by the FDA that the Company would not have to complete a CVOT to gain approval of ETC-1002. Then in a September 28, 2015 news release the Company noted that the FDA had actually “encouraged the Company to initiate a cardiovascular outcomes trial promptly” and it may be necessary to have a completed CVOT prior to approval.
If you suffered a loss in Esperion you have until March 14, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/esperion-espr.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
